Recent Advances in Inflammation & Allergy Drug Discovery最新文献_第3页

Modeling Inflammatory Bowel Disease by Intestinal Organoids. 肠道类器官模拟炎症性肠病

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221121143853

Cristina Di Giorgio, Rosalinda Roselli, Michele Biagioli, Martina Bordoni, Patrizia Ricci, Angela Zampella, Eleonora Distrutti, Annibale Donini, Stefano Fiorucci

{"title":"Modeling Inflammatory Bowel Disease by Intestinal Organoids.","authors":"Cristina Di Giorgio, Rosalinda Roselli, Michele Biagioli, Martina Bordoni, Patrizia Ricci, Angela Zampella, Eleonora Distrutti, Annibale Donini, Stefano Fiorucci","doi":"10.2174/2772270817666221121143853","DOIUrl":"https://doi.org/10.2174/2772270817666221121143853","url":null,"abstract":"Inflammatory bowel disease (IBD) is a chronic and relapsing disease caused by a dysregulated immune response to host intestinal microbiota that occurs in genetically predisposed individuals. IBD encompasses two major clinical entities: ulcerative colitis (UC), limited to the colonic mucosa, and Crohn's disease (CD), which might affect any segment of the gastrointestinal tract. Despite the prevalence of IBD increasing worldwide, therapy remains suboptimal, largely because of the variability of causative mechanisms, raising the need to develop individualized therapeutic approaches targeted to each individual patient. In this context, patients-derived intestinal organoids represent an effective tool for advancing our understanding of IBD's pathogenesis. Organoid 3D culture systems offer a unique model for dissecting epithelial mechanisms involved IBDs and testing individualized therapy, although the lack of a functional immune system and a microbiota, two driving components of the IBD pathogenesis, represent a major barrier to their exploitation in clinical medicine. In this review, we have examined how to improve the translational utility of intestinal organoids in IBD and how co-cultures of 3D or 2D organoids and immune cells and/or intestinal microbiota might help to overcome these limitations.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"39-53"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatitis E virus and Zoonosis: Recent Advances and Therapeutic Implications. 戊型肝炎病毒和人畜共患病:最新进展和治疗意义。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230112123221

Kam Lun Ellis Hon, Alexander K C Leung, Alex Wong, Siddharth Sridhar

{"title":"Hepatitis E virus and Zoonosis: Recent Advances and Therapeutic Implications.","authors":"Kam Lun Ellis Hon, Alexander K C Leung, Alex Wong, Siddharth Sridhar","doi":"10.2174/2772270817666230112123221","DOIUrl":"https://doi.org/10.2174/2772270817666230112123221","url":null,"abstract":"Hepatitis E is viral hepatitis caused by infection with the hepatitis E virus (HEV). This article aims to review HEV disease and recent advances in the management of hepatitis E. We used PubMed Clinical Queries and keywords of \"hepatitis E\", \"hepatitis E virus\" AND \"zoonosis\" as the search engine. \"Therapy\", \"Clinical Prediction Guides\", \"Diagnosis\", \"Etiology\" and \"Prognosis\" were used as filters, and \"Narrow\" scope was used. The search was conducted in April 2022. The information retrieved from the above search was used in the compilation of the present article. Hepatitis E is viral hepatitis caused by infection with the hepatitis E virus (HEV). Hepatitis E has mainly a fecal-oral transmission route. Hepatitis E infection usually follows an acute and self-limiting course of illness with low death rates in resource-rich areas; however, it can be more severe in pregnant women and immunocompromised people. The mortality rates in these groups are substantially higher. A vaccine for HEV is available but is not universally approved. Ribavirin remains the most efficacious medication for the treatment of HEV but is contraindicated in pregnancy. Sofosbuvir and pegylated interferon, with or without ribavirin, have not been shown in the latest literature reviews to provide reliable additional benefits to the treatment of hepatitis. Sofosbuvir should not be used as monotherapy for HEV. Food is an important source of infection in many countries while rats are the primary vector in developing nations. Management must include an understanding of the rat habitats for this zoonotic disease. Hepatitis E remains an important cause of hepatitis and a zoonotic disease globally. Public health policies are key to containing this viral infectious disease, including policy in the transfusion of blood products.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"54-63"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes. 抗cd3抗体和抗cd20抗体:治疗和预防1型糖尿病的免疫治疗策略综述

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666221122103029

Prajakta Kashalikar, Shivani Desai, Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde

{"title":"Narrative Review of Anti-CD3 Antibody and Anti-CD20 Antibody: Immunotherapeutic Strategies to Treat and Prevent Type 1 Diabetes.","authors":"Prajakta Kashalikar, Shivani Desai, Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde","doi":"10.2174/2772270817666221122103029","DOIUrl":"https://doi.org/10.2174/2772270817666221122103029","url":null,"abstract":"Background and objective: Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control, and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack.Methods: Based on preclinical and clinical data, we have discussed some immunotherapeutic in this meta-analysis. We referred to the preclinical and clinical studies for teplizumab and rituximab from authentic databases and compiled the data. We used statistical analysis to do a meta-analysis.Results: In two immunotherapeutic anti-CD3 antibodies and anti-CD20 antibodies examples, teplizumab and rituximab, respectively, shows better efficacy as well as fewer side effects. We have discussed this drug briefly based on their mechanism of action and meta-analysis, which compare clinical efficacy.Conclusion: Immunotherapeutic can be a better option for preventing and protecting type one diabetes. Since, the existing literature does not have enough data to support any single drug concluding the same will not be appropriate. Hence further studies are required wherein different drugs can be compared with similar sample sizes for each group of drugs.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"64-70"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Anti-arthritic and Antioxidant Effects of Trehalose in an Experimental Model of Arthritis. 海藻糖在关节炎实验模型中的抗关节炎和抗氧化作用。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230825093141

Fatemeh Forouzanfar, Mohammad Moein Vakilzadeh, Ali Mehri, Ali Mohammad Pourbagher-Shahri, Shiva Ganjali, Mitra Abbasifard, Amirhossein Sahebkar

{"title":"Anti-arthritic and Antioxidant Effects of Trehalose in an Experimental Model of Arthritis.","authors":"Fatemeh Forouzanfar, Mohammad Moein Vakilzadeh, Ali Mehri, Ali Mohammad Pourbagher-Shahri, Shiva Ganjali, Mitra Abbasifard, Amirhossein Sahebkar","doi":"10.2174/2772270817666230825093141","DOIUrl":"10.2174/2772270817666230825093141","url":null,"abstract":"Background: The purpose of the present study was to study the potential anti-arthritic and antioxidant effects of trehalose in an experimental model of complete Freund's adjuvant (CFA)-induced arthritis.Methods: Arthritis was induced via subcutaneous injection of CFA (0.1) into the right footpad of each rat. Trehalose (10 mg/kg per day) and indomethacin (5 mg/kg) as a reference drug were intraperitoneally injected into CFA-induced arthritic rats from days 0 to 21. Changes in paw volume, pain responses, arthritic score, and oxidative/antioxidative parameters were determined.Results: Trehalose administration could significantly decrease arthritis scores (p <0.01) and paw edema (p <0.001), and significantly increase the nociceptive threshold (p <0.05) in CFA-induced arthritic rats. Trehalose also significantly reduced the pro-oxidant-antioxidant balance values when compared to CFA treatment alone. In addition, no significant difference was found between the trehalose group and indomethacin as a positive control group.Conclusion: The current study suggests that trehalose has a protective effect against arthritis, which may be mediated by antioxidative effects of this disaccharide.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"145-151"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10444484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between Cardiac Atrioventricular Conduction and Antibodies to Chlamydia Pneumoniae in Fibromyalgia Patients. 纤维肌痛患者心脏房室传导与肺炎衣原体抗体的关系

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230705140935

Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach

{"title":"Association between Cardiac Atrioventricular Conduction and Antibodies to Chlamydia Pneumoniae in Fibromyalgia Patients.","authors":"Basant K Puri, Georgia Tuckey, Lucy Cowans, Gary S Lee, Armin Schwarzbach","doi":"10.2174/2772270817666230705140935","DOIUrl":"10.2174/2772270817666230705140935","url":null,"abstract":"Background: Fibromyalgia patients may complain of cardiovascular symptoms, including chest pain and palpitations. It has been proposed that infection by Chlamydia pneumoniae might be common in fibromyalgia. Chlamydia pneumoniae infection has also been hypothesized to be a causative factor in cardiac disease.Objective: This study aims to test the hypothesis that there is an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia.Methods: Thirteen female fibromyalgia patients underwent serum Chlamydia pneumoniae IgG assays and 12-lead electrocardiography in a cross-sectional study. None of the patients was taking medication which might affect atrioventricular conduction, and none suffered from hypothyroidism, renal disease, hepatic disease, or carotid hypersensitivity.Results: There was a significant positive correlation between the PR interval duration and the serum Chlamydia pneumoniae IgG level (r = 0.650; p = 0.016).Conclusion: This study supports the hypothesis of an association between atrioventricular conduction and antibodies to Chlamydia pneumoniae in fibromyalgia patients. It suggests that the higher the level of such antibodies, the greater the electrocardiographic PR interval, and therefore the slower the atrioventricular conduction. Potential pathophysiological mechanisms include a chronic inflammatory response to Chlamydia pneumoniae and the action of the bacterial lipopolysaccharide. The latter may involve stimulators of interferon genes, activation of the cardiac NOD-like receptor protein 3 inflammasomes, and downregulation of fibroblast growth factor 5 in the heart.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"127-132"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice. 新型n -芳基邻苯二胺衍生物在小鼠体内的镇痛活性。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230302145537

Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi

{"title":"In vivo Analgesic Activity of New N-arylphthalimides Derivatives in Mice.","authors":"Asghar Davood, Atefeh Saadabadi, Porya Torkaman, Ehsan Salehi, Hamed Shafaroodi","doi":"10.2174/2772270817666230302145537","DOIUrl":"10.2174/2772270817666230302145537","url":null,"abstract":"Background: A series of phthalimides related to thalidomide have been studied for analgesic activity in the formalin test. The formalin test was performed in mice in a nociceptive pattern to evaluate analgesic activity.Methods: In this study, nine derivatives of phthalimides were evaluated in terms of exerting analgesic effects in mice. They exerted significant analgesic effects compared to indomethacin and negative control. These compounds were synthesized and characterized by TLC, followed by IR and H1NMR in the previous studies. Two distinct periods of high licking activity were used to analyze both acute and chronic pain. All compounds were compared with indomethacin and carbamazepine as positive control and vehicle as a negative control.Results: All of the tested compounds exhibited significant analgesic activity in both the first and second phases of the test compared to the control group (DMSO), although they did not show more activity than the reference drug (indomethacin) but were comparable to indomethacin.Conclusion: This information may be useful in the development of a more potent phthalimide as an analgesic agent that acts as a sodium channel blocker and COX inhibitor.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"121-126"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9380191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Complex Regional Pain Syndrome (CRPS): New Perspectives in the use of Sulfonamides as Modulators of P2X Receptors. 复杂局部疼痛综合征(CRPS)的治疗:磺胺类药物作为P2X受体调节剂的新视角

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320124000

Giulia Culletta, Anna Maria Almerico, Marco Tutone

引用次数: 0

Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in Salmonella Typhimurium: Biocomputational Methods. 鼠伤寒沙门菌效应诱导免疫刺激的病理生理结构:生物计算方法。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230515125053

Abhigyan Choudhury

{"title":"Structural Insights to the Pathophysiology of Effector Induced Immunostimulation in Salmonella Typhimurium: Biocomputational Methods.","authors":"Abhigyan Choudhury","doi":"10.2174/2772270817666230515125053","DOIUrl":"10.2174/2772270817666230515125053","url":null,"abstract":"Introduction: The worldwide impact of the foodborne pathogen Salmonella can never be overstated, nor can be the fatal threat of septicemia in patients infected with its Typhimurium serovar. Behind the hyperimmune response in the case of septicemia lies a critical phenomenon of the bacterial pathogenic signals being sensed by different pattern recognition receptors, such as the Typhimurium effector proteins that are detected by toll-like receptors.Methods: To mitigate such a threat, precise structural and functional description of these effectors is necessary. The same has been addressed in this article using accelerated biocomputational techniques, beginning with the identification of the functional niche of the effectors and their influence over other proteins.Results: The molecular crystal structures were retrieved, and rigorous molecular docking experiments were conducted among the TLRs and effector proteins in order to examine the interactions. The interactions were thereby evaluated and screened according to their respective strengths using parameters including binding affinity, dissociation constant, hydropathy variation, etc. SopB effectors were found to be detected by three different TLR proteins and GtgE by two other TLRs, while SifA, SrfJ, and SsaV had only a single interacting TLR partner each. Interestingly, TLR9 presented lower sensitivity towards PAMPs of this bacterium.Conclusion: Normal modal analyses in combination with atomistic molecular dynamics simulations that tend to imitate natural cytosolic environments reveal stable and consistent interactions and realistic conformations among the effector-bound TLR complexes. The findings open up new avenues for the development of targeted therapies against Salmonella, which could significantly reduce the global burden of this foodborne pathogen.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":" ","pages":"133-144"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9475017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aeroallergen-specific Immunotherapy and Biologics Co-administration: Cost-benefit Re-considerations are Urgently Needed. 空气过敏原特异性免疫治疗和生物制剂联合给药:迫切需要重新考虑成本效益。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230320153734

George N Konstantinou, Maria Petrodimopoulou

引用次数: 0

Nano-Phytopharmaceuticals in Inflammation. 炎症中的纳米植物药物。

IF 0.4

Recent Advances in Inflammation & Allergy Drug Discovery Pub Date : 2023-01-01 DOI: 10.2174/2772270817666230123121836

Akhila S, Remya K

{"title":"Nano-Phytopharmaceuticals in Inflammation.","authors":"Akhila S, Remya K","doi":"10.2174/2772270817666230123121836","DOIUrl":"https://doi.org/10.2174/2772270817666230123121836","url":null,"abstract":"Inflammation is a defense mechanism of the body against harmful stimuli/organisms. Even if it is the body's defense mechanism, these mediators may affect different ways in the human body and can lead to chronic disorders. The most common treatment strategy for the acute type of inflammation mainly includes synthetic chemical drugs; Non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressant drugs whereas these synthetic drugs have many side effects, adverse effects, and limitations. Herbal drugs can be a promising alternative to these synthetic drugs but they too have limitations. Recent advances in the nanotechnology field can be combined with herbal drugs to overcome the limitations. Research works done on topical nanophyto pharmaceuticals for anti-inflammatory activity were compiled and in all the studies, clear evidence is indicated for the increased penetration, distribution, and increased efficacy of phytopharmaceuticals when formulated into nano dosage forms. Considering the adverse effects and limitations of most widely used synthetic drugs, topical nano Phyto pharmaceuticals can play a pivotal role in the local and systemic delivery of promising phytoconstituents to a specific site of the body.","PeriodicalId":29815,"journal":{"name":"Recent Advances in Inflammation & Allergy Drug Discovery","volume":"17 1","pages":"31-38"},"PeriodicalIF":0.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9933882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0